| 2003 |
NordMedica is founded by two senior executives with several years of international management experience from research based pharmaceutical companies, like Merck Sharpe and Dohme, Upjohn, Bayer and AstraZeneca. |
| 2005 |
6 proprietary products are acquired from Eli Lilly, US for Denmark and Iceland. Keflex®, Kefzol®, Nebcina®, Doloxene®, Vancocin® and Dobutrex®. |
| 2006 |
Vancocin® is acquired from Eli Lilly, US for the Swedish market. |
| 2006 |
Neostigmin is acquired from Pfizer, US for the Swedish market. |
| 2007 |
5 products are acquired from Pfizer for Sweden. Vibramycin®, Terramycin® with Polymyxin B, flurablastin, Adriamycin®, chloramphenicol succinat. Vibramycin® Oral suspension is also acquired for Norway, Finland, The Netherlands, Belgium and Luxembourg. |
| 2007 |
Pondocillin® is acquired for Denmark from Leo Pharma, Denmark. |
| 2008 |
Amekrin®/Amsidyl®/Amsidine® is acquired from Pfizer for Sweden, Germany, Switzerland, The Netherlands, Belgium and Luxembourg. Further rights for Amecrin in “compassionate use” for several international markets. |
| 2008 |
Flurablastin and Adriamycin® is divested to Strides Arcolab and Vancocin® i.v. is divested to Farma Plus, Norway. |
| 2008 |
Ampicillin is acquired for Denmark from Vepidan, Denmark. |
| 2008 |
NordMedica SA is established as a principal subsidiary in Lugano, Switzerland. Managing Director for the company employed. |
| 2009 |
FarmaPlus establishes their own distribution in Denmark after 4 successful years of collaboration with NordMedica. |
| 2009 |
The market authorisation for Nebcina® is transferred to Eurocept International B.V., The Netherlands. |
| 2009 |
NordMedica completes the acquisition of the product Estradurin® (polyestradiol) from Pfizer for 11 European countries. |
| 2010 |
A Nordic product portfolio of 8 products - Ampicillin, Dobutrex®, Doloxene®, Keflex®, Kefzol®, Neostigmin®, Pondocillin®, and Vancocin® - is divested to Pharmacodane ApS, a subsidiary of German STADA Arzneimittel AG. |
| 2010 |
The NordMedica headquarter is successfully relocated to Jægersborg Allé 164, 2820 Gentofte, Denmark. |
| 2011 |
NordMedica A/S acquires worldwide rights to RescueFlow® from BioPhausia AB, Sweden. RescueFlow® (7.5% sodium chloride and 6% dextran 70) is a novel Small Volume Resuscitation drug. |
| 2011 |
An agreement is signed with Goldshield Group Ltd, Surrey, UK by which the British and the Irish MA for Amsidine® is transferred to NordMedica. Goldshield will continue to act as distributor for Amsidine® in the 2 countries. |
| 2011 |
At a Board of Directors Meeting it is decided for NordMedica A/S to acquire a majority shareholding in the Danish company CCURE A/S from Chr. Olesen & Co. A/S. CCURE A/S is a pharmaceutical development company focused on bringing a range of basic pharmaceutical products to market in prefilled syringes. www.ccurepharma.com |
| 2011 |
The veterinary product rights for Doxynord® Vet is divested to Let Vet Pharma BV, The Netherlands. |
| 2011 |
NordMedica aquired a Danish portfolio of 5 well established products from Amgros (The Danish Regions' Pharmaceutical Organisation). |
